By Brazil Stock Guide – Dasa, one of Brazil’s largest diagnostic medicine and healthcare companies, posted a net loss of R$175.6 million ($31.8 million) in the second quarter of 2025, a 74% increase from a year earlier. The results, reported by Valor Econômico on Thursday, were hit by the transaction with Amil that carved out the company’s hospital network. Revenue fell 37.7% to R$2.7 billion from April to June.
The diagnostic medicine unit was the only segment to grow, with revenue up 6% year-over-year to R$2.1 billion. Earnings before interest, taxes, depreciation and amortization (Ebitda) rose 10% to R$738 million, which Dasa attributed to “operational improvements and accounting impacts from the formation of the joint venture” with Amil.
As part of the restructuring, about R$3.5 billion in debt was transferred to the new hospital company, reducing Dasa’s leverage from 4.24 times to 2.82 times Ebitda. Operating cash generation in the quarter totaled R$44 million.
Leave a Reply